2. Apoptosis Anti-infection
  3. Necroptosis RIP kinase Influenza Virus
  4. UH15-38

UH15-38 is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury.

For research use only. We do not sell to patients.

UH15-38 Chemical Structure

UH15-38 Chemical Structure

CAS No. : 2540881-21-6

Size Price Stock Quantity
5 mg USD 370 In-stock
10 mg USD 600 In-stock
25 mg USD 1200 In-stock
50 mg USD 1920 In-stock
100 mg USD 3080 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

UH15-38 Related Antibodies

Top Publications Citing Use of Products

View All RIP kinase Isoform Specific Products:

View All Isoforms
RIPK1 RIPK2 RIPK3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

UH15-38 is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury[1].

IC50 & Target[1]

RIPK3

20 nM (IC50)

In Vitro

UH15-38 (0-1000 nM; 12 h) decreases the expression of pMLKL induced by TCZ in a dose-dependent manner[1].
UH15-38 (0-1000 nM) protects type I alveolar epithelial cells from canonical TNF-induced necroptosis and prevents IAV-induced necroptosis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

UH15-38 Related Antibodies

Western Blot Analysis[1]

Cell Line: mouse embryonic fibroblasts
Concentration: 0, 25, 50, 100, 250, 500, 750, 1000 nM
Incubation Time: 12 h
Result: Decreased the expression of pMLKL induced by TCZ (mouse TNF (100 ng/ml), cycloheximide (250 ng/ml) and zVAD (50 μM)) in a time dependent manner.
In Vivo

UH15-38 (30 mg/kg; i.p.; daily for 4 days) dampens IAV (influenza A virus)-induced lung injury[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57Bl/6 mice (lethal dose of PR8 (6,000 × EID50))[1]
Dosage: 30 mg/kg
Administration: I.p.; once daily for 4 days; starting 24 h after infection
Result: Markedly reduced numbers of pMLKL+ necroptotic cells, decreased in diffuse alveolar damage and the formation of hyaline membranes, reduced the extent of fibrotic lung damage, displayed significantly lower levels of the pro-fibrotic mediators (IL-1β, IL-6, IL-18, IL-17 and CCL5).
Molecular Weight

441.52

Formula

C26H27N5O2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CN1CCN(CC1)C2=CC(NC3=NC=C4C=C(C(N(C4=C3)C)=O)C5=CC(O)=CC=C5)=CC=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (226.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2649 mL 11.3245 mL 22.6490 mL
5 mM 0.4530 mL 2.2649 mL 4.5298 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 5 mg/mL (11.32 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 5 mg/mL (11.32 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2649 mL 11.3245 mL 22.6490 mL 56.6226 mL
5 mM 0.4530 mL 2.2649 mL 4.5298 mL 11.3245 mL
10 mM 0.2265 mL 1.1325 mL 2.2649 mL 5.6623 mL
15 mM 0.1510 mL 0.7550 mL 1.5099 mL 3.7748 mL
20 mM 0.1132 mL 0.5662 mL 1.1325 mL 2.8311 mL
25 mM 0.0906 mL 0.4530 mL 0.9060 mL 2.2649 mL
30 mM 0.0755 mL 0.3775 mL 0.7550 mL 1.8874 mL
40 mM 0.0566 mL 0.2831 mL 0.5662 mL 1.4156 mL
50 mM 0.0453 mL 0.2265 mL 0.4530 mL 1.1325 mL
60 mM 0.0377 mL 0.1887 mL 0.3775 mL 0.9437 mL
80 mM 0.0283 mL 0.1416 mL 0.2831 mL 0.7078 mL
100 mM 0.0226 mL 0.1132 mL 0.2265 mL 0.5662 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

UH15-38 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

UH15-382540881-21-6NecroptosisRIP kinaseInfluenza VirusReceptor-interacting protein kinasesRIPKinfluenza A viruspMLKLlung injurynecroptosisinflammationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
UH15-38
Cat. No.:
HY-158312
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.